A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Trial Profile

A Randomized Phase III Study of Follow Up With or Without Adjuvant Gefitinib (Iressa) Following Chemotherapy in Patients With Advanced Non-Small Cell Lung Cancer.

Discontinued
Phase of Trial: Phase III

Latest Information Update: 13 Jul 2012

At a glance

  • Drugs Gefitinib (Primary)
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 Jul 2012 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 28 Jul 2011 Results published in the European Journal of Cancer.
    • 28 Jul 2011 Enrollment into this trial was ended prematurely with 173 patients due to low accrual, accoring to a paper published in the European Journal of Cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top